eddyDr. Eddy Chen is a physician-scientist trained in medical oncology. His research theme is to develop clinically useful biomarker assays to help patients and oncologists manage malignancies in an optimal manner that benefits individual patients and society. His focus has been on evaluating the dynamics of tumor specific plasma nucleic acids as surrogate markers for treatment response in prostate cancer therapy. He also has been enriching circulating tumor cells from prostate cancer patients to study mechanisms of resistance in different prostate cancer therapies.

Dr. Chen did his undergraduate studies at MIT. Afterwards, he became a research associate at Amgen, Inc, for several years working in their cancer biology labs. He then obtained his medical degree at the University of Southern California, and completed his internal medicine residency at Boston Medical Center, where he was also a Chief Resident. Subsequently, he completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, during which he started his research work with Dr. Steven Balk. He currently works at Dana-Farber. He continues to actively see cancer patients in the clinic setting as well as hospitalized patients, in addition to pursuing his translational research interests. Dr. Chen welcomes new opportunities for collaboration in the spirit of improving the management of oncology patients.


  1. Chen E , Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RT, Kantoff P, Montgomery B, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors (2015). Clin Cancer Res.

  2. Chen EJ , Sun J, Williams A, Moyle M, Koeffler HP, Gudas JM. “Different Subsets of Genes are Regulated by Vitamin D3 and the Vitamin D3 Analog EB1089 in Human Breast and Prostate Cancer Cells.” AACR 91st Annual Meeting, The Moscone Center, San Francisco, CA (2000)

  3. Chen EJ , Sun J and Gudas J: “The Vitamin D Receptor: A Ligand Activated Tumor Suppressor Gene.” Fourteenth Annual Meeting on Oncogenes, Salk Institute, La Jolla, California, (1998)

  4. Chen EJ , and Gudas J: “Dysregulation of p27/Kip1 in Breast Cancer Cells.” Gordon Conference on Cancer, Salve Regina University, Newport, Rhode Island, (1997)

Link to Dr. Chen's Harvard Catalyst Page